Skip to main content
Caplight Logo









Proxygen

Proxygen

Private
ViennaHealthcare & Life Scienceshttps://proxygen.com/

Last Round

Strategic

Apr 5, 2023

Total Funding Raised

$250,000

Company Overview

Proxygen is a biotechnology company developing a new class of therapeutics based on induced proximity to address high-value targets in oncology and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

molecular glue degradersmolecular glue discoveryundruggable targetsdrug discovery platformtargeted protein degradationTPDinduced proximitypharmaceutical partnershipssmall molecule drugsprotein degradationcancer therapeuticsdrug licensingproteomicsAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Proxygen Comparables

Compare Proxygen with similar companies based on industry and business-model similarity.

Proxygen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neomorph
89%
Degron Therapeutics
88%
Plexium
88%

Proxygen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicApr 5, 2023
StrategicJun 2, 2022
StrategicDec 7, 2020
GrantJul 31, 2020

Key People

Founding team and executive leadership

Matthias Brand

Chief Technology Officer, Co-founder, Chief Scientific Officer, Co-founder

Founding Team

Bernd Boidol

CEO

Executive Team

Proxygen Investors

Notable investors and investment history

Proxygen investors
InvestorRounds
Boehringer IngelheimGrant, Strategic
WlanholdingSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors grew 49% MoM.

  • Aug 8, 2023

    Grew 30% QoQ, from 23 to 30 employees.

Proxygen Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Proxygen Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Proxygen's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Employee Range36
Year Founded2020
Last FundingApr 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?